Metoprolol-Acrihin, tablets 50 mg 30 pcs

Metoprolol belongs to the cardioselective β-adrenoreceptor blockers with no intrinsic sympathomimetic activity and membrane stabilizing properties. It has hypotensive, antianginal and antiarrhythmic effects.

Blocking in low doses the β-adrenoreceptors of heart, it decreases catecholamine-stimulated formation of cAMP from ATP, decreases intracellular Ca2+ flow, produces negative chrono-, dromo-, batmo- and inotropic action (decreases heart rate, inhibits conduction and excitability and decreases myocardial contractility).

The total peripheral resistance at the beginning of β-adrenoblocker administration (in the first 24 h after oral administration) – increases (as a result of reciprocal increase of α-adrenoreceptor activity and elimination of β-adrenoreceptor stimulation), which returns to baseline after 1-3 days, and decreases with long-term administration.

. Acute antihypertensive effect is due to a decrease in cardiac output, a stable antihypertensive effect develops over 2-3 weeks and is due to a decrease in renin synthesis, and plasma renin accumulation, Inhibition of renin-angiotensin system activity (of great importance in patients with initial renin hypersecretion) and CNS restoration of aortic arch baroreceptors sensitivity (there is no increase of their activity in response to blood pressure decrease) and, finally, reduction of peripheral sympathetic effects. Reduces elevated BP at rest, under physical stress and strain.

The antianginal effect is determined by reducing myocardial oxygen demand as a result of decreased heart rate (prolongation of diastole and improvement of myocardial perfusion) and contractility, as well as decreased myocardial sensitivity to the effects of sympathetic innervation. It reduces the number and severity of angina attacks and increases exercise tolerance. Blood pressure decreases in 15 minutes, maximum in 2 hours and lasts for 6 hours; diastolic BP changes slower: stable decrease is observed after several weeks of regular use.

The antiarrhythmic effect is caused by the elimination of arrhythmogenic factors (tachycardia, increased activity of the sympathetic nervous system, increased content of CAMF, arterial hypertension), the decrease of spontaneous excitation rate of sinus and ectopic pacemakers and AV conduction slowing down (mainly in antegrade and, to smaller extent, in retrograde direction via AV node) and via additional pathways. In supraventricular tachycardia, atrial fibrillation, sinus tachycardia in functional heart disease and hyperthyroidism, it reduces the heart rate, or may even lead to restoration of sinus rhythm. Prevents the development of migraine.

In medium therapeutic doses, unlike non-selective beta-adrenoblockers, it has less effect on the organs containing β-adrenoreceptors (pancreas, skeletal muscles, smooth muscles of peripheral arteries, bronchi and uterus) and on carbohydrate metabolism. When used in high doses (more than 100 mg/day) it has a blocking effect on both β-adrenoreceptor subtypes.

PHARMACOKINETICS

Metoprolol is rapidly and almost completely (95%) absorbed in the gastrointestinal tract. Cmax in blood plasma is reached 1-2 hours after oral administration. T1/2 is on average 3.5 h (range 1 h to 9 h).

The bioavailability is 50% when administered for the first time and increases to 70% when administered repeatedly. Food intake increases bioavailability by 20-40%. Bioavailability of metoprolol increases in liver cirrhosis. The binding to plasma proteins averages 10%.

The drug penetrates through the blood-brain and placental barriers. It is excreted in breast milk in small amounts.

It is metabolized in the liver. Metabolites have no pharmacological activity. About 5% of the drug is excreted unchanged by the kidneys. Treatment of patients with impaired renal function does not require correction of the drug dose. Impaired liver function slows down the drug metabolism and in cases of poor liver function, the drug dose should be reduced. It is not eliminated by hemodialysis.

Indications

Active ingredient

Composition

1 tablet contains:

The active ingredients:

metoprolol tartrate 50 mg.

Auxiliary substances:

colloidal anhydrous silica,

microcrystalline cellulose,

sodium carboxymethyl starch (type A),

magnesium stearate.

The composition of the shell:

hypromellose,

polysorbate 80,

talc,

titanium dioxide (E171).

How to take, the dosage

Overly, with food or immediately after a meal, without chewing and with liquids.

Arterial hypertension: the initial daily dose is 50-100 mg in 1-2 doses (morning and evening). In case of insufficient therapeutic effect the daily dose may be gradually increased to 100-200 mg and/or other antihypertensive agents may be prescribed in addition.

The maximum daily dose is 200 mg.

Stenocardia, arrhythmias, prevention of migraine attacks: 100-200 mg daily in two doses (morning and evening).

Secondary prevention of myocardial infarction: 200 mg per day in two doses (morning and evening).

Functional cardiac disorders with tachycardia: 100 mg per day in two doses (morning and evening).

In elderly patients, in patients with impaired renal function, and if hemodialysis is necessary, the dose is not changed.

In patients with hepatic impairment the dose of the drug should be reduced depending on the clinical condition.

Interaction

Combined use with monoamine oxidase inhibitors (MAOIs) is not recommended due to a significant increase in the hypotensive effect. A treatment interval between MAO inhibitors and metoprolol should be at least 14 days.

Concomitant intravenous administration of verapamil may induce cardiac arrest. Simultaneous administration of nifedipine leads to a significant decrease in BP.

The agents for inhalation anesthesia (hydrocarbon derivatives) increase the risk of myocardial depression and arterial hypotension.

Beta-adrenergic stimulants, theophylline, cocaine, estrogens (sodium retention), indomethacin and other non-steroidal anti-inflammatory drugs (sodium retention and blocking of prostaglandin synthesis by the kidneys) weaken the hypotensive effect.

There is marked an increased suppressive effect on the central nervous system – with ethanol; summation of the cardiodepressant effect – with anesthetics; increased risk of peripheral circulatory disorders – with ergot alkaloids.

When co-administered with oral hypoglycemic agents, their effect may be decreased; with insulin – increased risk of hypoglycemia, its increased severity and prolongation, masking of some symptoms of hypoglycemia (tachycardia, sweating, increased BP).

When combined with hypotensive agents, diuretics, nitroglycerin or slow calcium channel blockers, a sharp decrease in BP may develop (special caution is necessary when combined with prazosin ); increased severity of HR slowing and suppression of atrioventricular conduction when using metoprolol with verapamil, diltiazem, antiarrhythmic agents (amiodarone), reserpine, clonidine, guanfacine, agents for general anesthesia and cardiac glycosides.

Hepatic microsomal enzyme inducers (rifampicin, barbiturates) lead to increased metabolism of metoprolol and decreased plasma concentrations of metoprolol and reduced effect.

Inhibitors (cimetidine, oral contraceptives, phenothiazines) – increase plasma concentrations.

Allergens used for immunotherapy or allergen extracts for skin tests when combined with metoprolol increase the risk of systemic allergic reactions or anaphylaxis; iodine containing x-ray contrast agents for IV administration increase the risk of anaphylactic reactions.

Decreases clearance of xanthine (except diphylline), especially in patients with initially increased clearance of theophylline due to smoking. Reduces lidocaine clearance, increases plasma lidocaine concentrations. Increases and prolongs the effect of antidepolarizing myorelaxants; prolongs the anticoagulant effect of coumarins.

In co-administration with ethanol the risk of significant BP decrease increases.

Special Instructions

The monitoring of patients taking beta-adrenoblockers includes regular monitoring of HR and BP, blood glucose content in diabetic patients (once every 4-5 months).

If necessary for diabetic patients, the dose of insulin or oral hypoglycemic agents should be adjusted individually.

The patient should be taught how to calculate heart rate and instructed to consult a physician if the heart rate is less than 50 bpm.

If doses above 200 mg per day are taken, cardioselectivity decreases.

In heart failure, treatment with metoprolol is not started until the compensation stage is reached. It is possible to increase the severity of hypersensitivity reactions (with a history of allergic reactions) and the lack of effect of the usual doses of epinephrine (adrenaline). It may aggravate the symptoms of peripheral arterial circulatory disorders.

The drug is withdrawn gradually, reducing the dose over 10 days. If treatment is stopped abruptly, a “withdrawal” syndrome may occur (increased angina pectoris attacks, increased BP). Special attention should be given to patients with angina pectoris when withdrawing the drug.

In angina patients with tension angina, the selected dose of the drug should provide an HR at rest within 55-60 beats/min, and not more than 110 beats/min on exertion.

Patients who wear contact lenses should be aware that treatment with beta-adrenoblockers may decrease lacrimal fluid production.

Methoprolol may mask some clinical manifestations of thyrotoxicosis (e.g., tachycardia). Abrupt withdrawal in patients with thyrotoxicosis is contraindicated because it may exacerbate the symptoms.

In diabetic patients may mask tachycardia caused by hypoglycemia. Unlike non-selective beta-adrenoblockers, it practically does not increase insulin-induced hypoglycemia and does not delay the recovery of blood glucose concentration to normal levels.

In patients with bronchial asthma, beta 2-adrenoceptors are used as concomitant therapy; in pheochromocytoma, alpha-adrenoblockers are used.

If it is necessary to perform surgical intervention, the anesthesiologist must be warned about the therapy (choice of general anesthetic agent with minimal negative inotropic effect); cancellation of the drug is not recommended.

Drugs that decrease catecholamine stores (e.g., reserpine) may increase the effects of beta-adrenoblockers, so patients taking these combinations of drugs should be under constant medical monitoring for excessive BP reduction and bradycardia.

Patients with depressive disorders taking metoprolol should be monitored closely; if depression develops in response to beta-adrenoblocker therapy, therapy should be discontinued.

Wear appropriate clothing when treating with metoprolol, as the drug may cause allergic skin to sunlight.

In elderly patients, monitoring of liver function is recommended. The dosing regimen should be adjusted only in elderly patients with increasing bradycardia (less than 50 bpm), marked BP decrease (systolic BP below 100 mmHg), atrioventricular block, bronchospasm, ventricular arrhythmias, severe liver function abnormalities; sometimes the treatment must be stopped.

In the absence of sufficient clinical data, the drug is not recommended for use in children.

At the time of treatment it is necessary to refrain from driving motor transport and engaging in potentially hazardous activities requiring increased concentration and rapid psychomotor reactions, avoid taking ethanol.

Contraindications

Side effects

Nervous system disorders: increased fatigue, weakness, headache, slowed rate of mental and motor reactions; rarely – paresthesias in the extremities (in patients with claudication and Raynaud’s syndrome), depression, anxiety, reduced attention, drowsiness, insomnia, nightmares, confusion or short-term memory loss, muscle weakness.

Sensory organs: rarely – decreased vision, decreased tear fluid secretion, dry and sore eyes, conjunctivitis, tinnitus.

Cardiovascular system disorders: sinus bradycardia, palpitations, decreased BP, orthostatic hypotension, dizziness, sometimes loss of consciousness); rarely – decreased myocardial contractility, temporary worsening of symptoms of chronic heart failure (edema, swelling of the feet and/or lower legs, dyspnea), arrhythmias, angiospasm (increased peripheral circulatory disorders, coldness of the lower extremities, Raynaud’s syndrome), myocardial conduction disorders, cardialgia.

Digestive system disorders: nausea, vomiting, abdominal pain, dry mouth, diarrhea, constipation, liver function disorders, change in taste.

Skin disorders: urticaria, skin itching, rash, exacerbation of psoriasis, psoriasis-like skin reactions, skin hyperemia, exanthema, photodermatosis, increased sweating, reversible alopecia.

Respiratory system: nasal congestion, difficulty in exhaling (bronchospasm when prescribed in high doses – loss of selectivity and/or in predisposed patients), dyspnea.

Endocrine system: hypoglycemia (in patients receiving insulin), rarely: hyperglycemia (in patients with diabetes), hypothyroidism.

Laboratory parameters: rare: thrombocytopenia (unusual bleeding and hemorrhage), agranulocytosis, leukopenia, increased activity of liver enzymes; extremely rare: hyperbilirubinemia.

Fetal effects: possible intrauterine growth retardation, hypoglycemia, bradycardia.

Others: back or joint pain, like all beta-adrenoblockers in single cases may cause a slight increase in body weight, decreased libido and/or potency.

Overdose

Symptoms:

. severe sinus bradycardia, dizziness, nausea, vomiting, cyanosis, marked BP decrease, arrhythmia, ventricular extrasystole, bronchospasm, fainting, in acute overdose – cardiogenic shock, loss of consciousness, coma, atrioventricular block (up to development of complete transverse block and cardiac arrest), cardialgia.

The first signs of overdose occur 20 minutes to 2 hours after taking the drug.

Treatment:

gastric lavage and administration of adsorptive agents; symptomatic therapy: If there is a marked decrease in BP – the patient should be in the Trendelenburg position; in case of an excessive decrease in BP, bradycardia and heart failure – IV, at 2-5 minute intervals, ba-adrenergic stimulants – until the desired effect or IV 0.5-2 mg of atropine sulfate .

In the absence of a positive effect – dopamine, dobutamine or norepinephrine (noradrenaline). As a follow-up, prescription of 1-10 mg of glucagon, placement of transvenous intracardiac pacing may be possible. In bronchospasm, IV beta 1 -adrenoreceptor stimulants should be administered. Slow IV administration of diazepam in case of seizures. Hemodialysis is not effective.

Pregnancy use

Metoprolol is contraindicated in pregnancy, lactation, and children.

Similarities